Found: 17
Select item for more details and to access through your institution.
Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
- Published in:
- Pharmacology Research & Perspectives, 2019, v. 7, n. 6, p. 1, doi. 10.1002/prp2.543
- By:
- Publication type:
- Article
Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP.
- Published in:
- Journal of Clinical Investigation, 2008, v. 118, n. 1, p. 259, doi. 10.1172/JCI32011
- By:
- Publication type:
- Article
Comprehensive healthcare resource use among newly diagnosed congestive heart failure.
- Published in:
- Israel Journal of Health Policy Research, 2017, v. 6, p. 1, doi. 10.1186/s13584-017-0149-0
- By:
- Publication type:
- Article
Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 10, p. 1822, doi. 10.1002/ejhf.3021
- By:
- Publication type:
- Article
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 11, p. 2029, doi. 10.1002/ejhf.2720
- By:
- Publication type:
- Article
Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 5, p. 843, doi. 10.1002/ejhf.2481
- By:
- Publication type:
- Article
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 5, p. 782, doi. 10.1002/ejhf.2468
- By:
- Publication type:
- Article
Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 5, p. 1061, doi. 10.1002/cpt.2712
- By:
- Publication type:
- Article
Ion channels: Shake, rattle or roll?
- Published in:
- Nature, 2004, v. 427, n. 6974, p. 499, doi. 10.1038/427499a
- By:
- Publication type:
- Article
Treatment patterns of patients with worsening heart failure with reduced ejection fraction.
- Published in:
- ESC Heart Failure, 2024, v. 11, n. 4, p. 1932, doi. 10.1002/ehf2.14805
- By:
- Publication type:
- Article
Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY‐HFpEF trial.
- Published in:
- ESC Heart Failure, 2024, v. 11, n. 1, p. 293, doi. 10.1002/ehf2.14572
- By:
- Publication type:
- Article
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Tethered blockers as molecular ‘tape measures’ for a voltage-gated K<sup>+</sup> channel.
- Published in:
- Nature Structural Biology, 2000, v. 7, n. 4, p. 309
- By:
- Publication type:
- Article
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 6, p. 751, doi. 10.1007/s40262-024-01384-1
- By:
- Publication type:
- Article
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2458, doi. 10.1111/cts.13677
- By:
- Publication type:
- Article
HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization.
- Published in:
- 2017
- By:
- Publication type:
- journal article